SK Biopharm secures European actinium‑225 supply from Germany’s Eckert & Ziegler

CAR-T Digest - August 2020

03 December 2025: SK Biopharm secures European actinium‑225 supply from Germany’s Eckert & Ziegler

SK Biopharm has signed an agreement with Germany’s Eckert & Ziegler to secure a reliable supply of GMP-certified actinium-225, a key isotope required for the development of next-generation radiopharmaceutical therapies (RPT)
By establishing this partnership in Europe, SK Biopharm significantly strengthens supply chain independence and reduces reliance on North American sources for actinium-225, a material that remains scarce and highly sought after for advanced cancer treatment programs
The secured supply will enable SK Biopharm to accelerate its growing RPT pipeline, including SKL35501, which is preparing for a Phase 1 IND, as well as the company’s newly added candidate WT-7695, signaling rapid expansion of its radiotherapy portfolio
Actinium-225 plays a pivotal role in emerging oncology therapies due to its powerful tumor-killing properties paired with a lower side-effect burden, making it one of the most promising raw materials in the field of targeted radiation
Eckert & Ziegler expressed strong support for the collaboration, emphasizing that the partnership will help advance innovative cancer treatments by ensuring stable access to this critical therapeutic isotope